Blastic plasmacytoid dendritic cell neoplasm

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Martin W. Schoen, MD, MPH
Saint Louis University
St. Louis, MO

1 regimens on this page
1 variants on this page

All lines of therapy

Tagraxofusp monotherapy


Study Dates of enrollment Evidence
Frankel et al. 2014 (STU 012013-061) 2013-NR Phase 1/2, <20 pts
Pemmaraju et al. 2019 (STML-401-0114) 2014-2017 Phase 1/2 (RT)

Targeted therapy

21-day cycles


  1. STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed Clinical Trial Registry
  2. STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
    1. Update: Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. link to original article link to PMC article PubMed